{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:26:26Z","timestamp":1789619186246,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.ejca.2007.06.024","type":"journal-article","created":{"date-parts":[[2007,8,27]],"date-time":"2007-08-27T10:57:19Z","timestamp":1188212239000},"page":"2046-2051","source":"Crossref","is-referenced-by-count":140,"title":["111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumab-related cardiotoxicity"],"prefix":"10.1016","volume":"43","author":[{"given":"M.A.","family":"de Korte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.G.E.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Lub-de Hooge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.L.","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Gietema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.A.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.J.","family":"Sluiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"van Veldhuisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.M.","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.T.","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Perik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2007.06.024_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2007.06.024_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ejca.2007.06.024_bib3","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2007.06.024_bib4","unstructured":"Slamon D, Eiermann W, Robert N, et al., Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study, Proc San Antonio Breast Cancer Symposium, 2005 [abstract #1]."},{"issue":"31","key":"10.1016\/j.ejca.2007.06.024_bib5","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2007.06.024_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejca.2007.06.024_bib7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMp058315","article-title":"Herceptin and the heart \u2013 a molecular modifier of cardiac failure","volume":"354","author":"Chien","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.ejca.2007.06.024_bib8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"issue":"49","key":"10.1016\/j.ejca.2007.06.024_bib9","doi-asserted-by":"crossref","first-page":"51141","DOI":"10.1074\/jbc.M408662200","article-title":"Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta\/erbB4 signaling","volume":"279","author":"Kuramochi","year":"2004","journal-title":"J Biol Chem"},{"issue":"31","key":"10.1016\/j.ejca.2007.06.024_bib10","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2007.06.024_bib11","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2007.06.024_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"ErbB2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.ejca.2007.06.024_bib13","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1073\/pnas.122249299","article-title":"Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy","volume":"99","author":"Ozcelik","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.ejca.2007.06.024_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1023\/B:BREA.0000003916.39959.73","article-title":"Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin)","volume":"82","author":"Fuchs","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ejca.2007.06.024_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bjp.0705915","article-title":"Preclinical characterisation of 111In-DTPA-trastuzumab","volume":"143","author":"Lub-De Hooge","year":"2004","journal-title":"Br J Pharmacol"},{"issue":"15","key":"10.1016\/j.ejca.2007.06.024_bib16","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.2005.03.8448","article-title":"Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"24","author":"Perik","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2007.06.024_bib17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1053-2498(02)00390-X","article-title":"Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart","volume":"21","author":"Uray","year":"2002","journal-title":"J Heart Lung Transpl"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907005102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804907005102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T18:50:00Z","timestamp":1546627800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804907005102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":17,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0959804907005102"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2007.06.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}